SP has received education grants, provided consultation, attended advisory boards, or provided lectures for AbbVie, LC has served as consultant or advisor to Bristol-Myers Squibb and Merck Sharp and Dohme, 2017. ,
CG has received honoraria as consultant or advisor or speaker bureau member for AstraZeneca, Bristol-Myers Squibb, F Hoffmann-La Roche, and Merck Sharp and Dohme, and has received funds (to organisation) from Merck Sharp and Dohme. MR has served as a consultant and provided lectures for Amgen, Gritstone. AMDG has served as a consultant or advisor to Incyte, 2019. ,
, , 2020.
, COVID-19): cases in the US, Centers for Disease Control and Prevention. Coronavirus disease, 2019.
Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection, Radiology, 2020. ,
Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia, Radiology, vol.13, 2020. ,
Immune checkpoint inhibitors in thoracic malignancies: review of the existing evidence by an IASLC expert panel and recommendations, J Thorac Oncol, 2020. ,
PD-1 inhibitor-related pneumonitis in advanced cancer patients: Radiographic patterns and clinical course, Clin Cancer Res, vol.22, pp.6051-60, 2016. ,
Management of pulmonary toxicity associated with immune checkpoint inhibitors, Eur Respir Rev, vol.28, 2019. ,
Osimertinib in untreated EGFRmutated advanced non-small cell lung cancer, N Engl J Med, vol.378, pp.113-138, 2018. ,
Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized clinical trials, Ann Oncol, vol.31, pp.50-60, 2020. ,
Pulmonary toxicity of cytotoxic and immunosuppressive agents. A review, Acta Oncol, vol.29, pp.113-137, 1990. ,
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol, vol.21, pp.335-372, 2020. ,
, US Food & Drug Administration. Emergency use authorizations: in vitro diagnostics EUAs, 2020.